Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04060641Unknown

Association Between a Multi-Gene Panel and Renal Denervation Effectiveness in Patients With Hypertension

Role: lead

NCT02988245Phase 2Unknown

Investigating the Use of Genetics to Guide Pharmacologic Therapy for Hypertension

Role: lead

NCT03292900Completed

Association Between Genetic Algorithm to Predict Hypertension Therapy and Response to Treatment

Role: lead

NCT02524873Completed

Relationship Between Genes Important in Blood Pressure Regulation and Blood Pressure Therapy in Hypertension

Role: lead

All 4 trials loaded